VYNE Therapeutics Inc. (VYNE)
NASDAQ: VYNE · Real-Time Price · USD
1.310
+0.060 (4.80%)
May 13, 2025, 4:00 PM - Market closed
VYNE Therapeutics Employees
VYNE Therapeutics had 13 employees as of December 31, 2024. The number of employees increased by 3 or 30.00% compared to the previous year.
Employees
13
Change (1Y)
3
Growth (1Y)
30.00%
Revenue / Employee
$46,538
Profits / Employee
-$3,245,846
Market Cap
19.43M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VYNE News
- 6 days ago - VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 18 days ago - FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold - Benzinga
- 19 days ago - VYNE Therapeutics Provides Update on VYN202 Program - GlobeNewsWire
- 7 weeks ago - VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - GlobeNewsWire
- 2 months ago - VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - VYNE Therapeutics to Participate in March Investor Conferences - GlobeNewsWire
- 2 months ago - VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - GlobeNewsWire
- 4 months ago - VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo - GlobeNewsWire